Pre-clinical evaluation of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for imaging of insulinoma

Nuclear Medicine and Biology

Volumn 41, Issue 6, 2014, Pages 471-476

  Selvaraju, Ram Kumar ^a   Velikyan, Irina ^a,b   Asplund, Veronika ^a   Johansson, Lars ^a,c   Wu, Zhanhong ^d   Todorov, Ivan ^d   Shively, Jack ^d   Kandeel, Fouad ^d   Eriksson, Barbro ^b   Korsgren, Olle ^a   Eriksson, Olof ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Glucagon like peptide 1 receptor (GLP 1R); Insulinoma; Positron emission tomography (PET)

Indexed keywords

5 HYDROXYTRYPTOPHAN C 11; GA DO3A VS CYS40 EXENDIN 4 GA 68; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG; 1,4,7-TRIS(CARBOXYMETHYL)-10-(VINYLSULFONE)-1,4,7,10-TETRAAZACYCLODODECANE; EXENDIN 4; GALLIUM; PEPTIDE; SINGLE HETEROCYCLIC RINGS; VENOM; VINYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG SCREENING; DRUG UPTAKE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INSULINOMA; LUNG PARENCHYMA; MUSCLE TISSUE; NONHUMAN; PANCREAS; POSITRON EMISSION TOMOGRAPHY; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; TUMOR BIOPSY; TUMOR XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; RADIOCHEMISTRY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INSULINOMA; MICE; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RATS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; VENOMS; VINYL COMPOUNDS;

EID: 84901190958     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.03.017     Document Type: Article

References (26)

1. Soga J., Yakuwa Y. Pancreatic endocrinomas: a statistical analysis of 1857 cases. J Hepatobiliary Pancreat 1994, 1:522-529.
2. Öberg K., Eriksson B. Endocrine tumors of the pancreas. Best Pract Res Clin Haematol 2005, 19(5):753-781.
3. Aisha S., Lubna M.Z., Haque N. Recurrent insulinoma - rare among the rarities. J Coll Physicians Surg Pak 2007, 17(6):364-366.
4. Kimura W., Kuroda A., Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991, 36(7):933-942.
5. Grimelius L., Hultquist G.T., Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumors in autopsy material. Virchows Arch A Pathol Anat Histol 1975, 365(4):275-288.
6. Jensen R.T., Gibril F., Termanini B. Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. Yale J Biol Med 1997, 70(5-6):481-500.
7. Tornehave D., Kristensen P., Rømer J., Knudsen L.B., Heller R.S. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 2008, 56(9):841-851.
8. Körner M., Stöckli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007, 48(5):736-743.
9. Wild D., Mäcke H., Christ E., Gloor B., Reubi J.C. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008, 359(7):766-768.
10. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem 1992, 267(11):7402-7405.
11. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268(26):19650-19655.
12. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50(5):583-589.
13. Leech C.A., Dzhura I., Chepurny O.G., Kang G., Schwede F., Genieser H.G., et al. Molecular physiology of glucagon like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol 2011, 107(2):236-247.
14. Hongxiang H., Loredana F., Patricia M., Riccardo P. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002, 146(6):863-869.
15. Alan J.G. Long-acting glucagon-like peptide 1 receptor agonists. Diabetes Care 2011, 34(2):S279-S284.
16. Thum A., Hupe-Sodmann K., Göke R., Voigt K., Göke B., McGregor G.P. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 2002, 110:113-118.
17. Gao W., Jusko W.J. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther 2011, 336(3):881-890.
18. Egan J.M., Clocquet A.R., Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002, 87(3):1282-1290.
19. Briones M., Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 2006, 7(8):1055-1064.
20. 111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006, 47(12):2025-2033.
21. 18F]AlF-NOTA analog of Exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics 2012, 2(10):999-1009.
22. 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor. Bioconjug Chem 2011, 22(8):1587-1594.
23. Wild D., Wicki A., Mansi R., Behe M., Keil B., Bernhardt P., et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010, 51(7):1059-1067.
24. Körner M., Christ E., Wild D., Reubi J.C. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Review article. Front Endocrinol 2012, 3:158.
25. Shin J.J., Gorden P., Libutti S.K. Insulinoma: pathophysiology, localization and management. Future Oncol 2010, 6(2):229-237.
26. Sundin A., Garske U., Orlefors H. Nuclear imaging of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007, 21(1):69-85.